The goal of post-launch research is to monitor a drug or medical device after it reaches the general public, catching safety problems that pre-approval trials were too small to detect and confirming that the product actually works in everyday clinical practice. Pre-approval studies typically involve only several hundred to several thousand patients in tightly controlled settings. Post-launch research expands that lens to millions of diverse, real-world users over years or even decades.
Why Pre-Approval Trials Aren’t Enough
Before a drug reaches the market, it goes through phased clinical trials designed to prove it works and identify common side effects. These trials use highly selective populations: participants are screened against strict inclusion criteria, treated in controlled settings, and followed on fixed schedules. That approach produces reliable data on whether a drug works under ideal conditions, but it leaves significant gaps.
The biggest gap is sample size. A trial of 3,000 people simply cannot detect a side effect that occurs in fewer than 1 in 10,000 users. Some of the most serious reactions, like a severe skin condition called toxic epidermal necrolysis, occur in fewer than 2 people per million. One study used a database of over 4 million people and still found only 23 cases, too few to analyze which specific drugs were responsible. Post-launch research exists to fill that gap by drawing on data from vastly larger and more varied populations.
The other major limitation is representativeness. Trial participants tend to be younger, healthier, and more carefully monitored than the average patient who eventually fills a prescription. Older adults with multiple chronic conditions, pregnant women, and children are often excluded. Post-launch research captures what happens when these broader groups start using a product in real life, where doses get missed, other medications interact, and follow-up is less consistent.
Detecting Rare and Delayed Safety Problems
Safety monitoring is the most critical goal of post-launch research. The FDA maintains a reporting system called FAERS (the FDA Adverse Event Reporting System) where healthcare providers and patients can flag unexpected side effects. Teams of safety evaluators, epidemiologists, and scientists analyze these reports to detect new safety signals.
This system has real consequences. A Yale-led study analyzing drugs approved between 2001 and 2010 found that 32% of new medications were flagged for a previously unrecognized safety issue in the years after approval. Most of those cases didn’t result in the drug being pulled from the market. More commonly, the FDA responded by adding a boxed warning (the most serious type of label warning), issuing safety communications to physicians, or updating prescribing information. In rarer cases, a drug’s approval is re-evaluated entirely.
Some safety problems only emerge after years of use. A drug prescribed for a chronic condition might take five or seven years to reveal effects on the heart, liver, or kidneys. Pre-approval trials, which often last months to a few years, can’t capture these long-term risks. Post-launch surveillance fills that timeline.
Measuring Real-World Effectiveness
There’s an important distinction between efficacy and effectiveness. Efficacy is how well a drug works under the ideal, controlled conditions of a clinical trial. Effectiveness is how well it works in the messier reality of everyday medicine, where patients see different doctors, take multiple medications, and don’t always follow instructions perfectly.
Post-launch research focuses on effectiveness. It draws on electronic medical records, insurance claims databases, and patient registries to see how treatments perform across heterogeneous populations. This data can reveal that a drug works slightly better or worse than trials predicted, that it performs differently in certain age groups, or that patients frequently stop taking it due to side effects that weren’t prominent in trials.
One persistent challenge is measuring compliance. Electronic medical records can show whether a prescription was filled, but not whether the patient actually took the medication as directed. This makes it harder to draw firm conclusions about a drug’s real-world performance, which is why post-launch evidence complements rather than replaces trial data.
Expanding Uses and Updating Labels
Post-launch research also supports expanding a drug’s approved uses. A medication originally approved for one condition in adults might later be studied in children or tested against a different disease. These Phase 4 studies are sometimes imposed by the FDA as a condition of the original approval, requiring manufacturers to continue gathering specific data after launch.
Label updates go both directions. Safety findings can lead to new warnings or restricted use, while positive real-world data can support removing prescribing limitations or adding new indications. About 20% of reassessments by health technology assessment agencies are requested by the drug’s manufacturer, often to expand approved uses or remove prescribing restrictions based on accumulated post-launch evidence.
Influencing Drug Pricing and Insurance Coverage
Post-launch data increasingly shapes how drugs are priced and whether insurers cover them. Health technology assessment agencies worldwide use real-world evidence to reassess products after their initial coverage recommendation, often as part of conditional reimbursement agreements where continued coverage depends on demonstrating real-world value.
In the United States, the Inflation Reduction Act’s Medicare Drug Price Negotiation Program gives the government authority to negotiate prices on certain medications. These negotiations happen 7 to 11 years after a drug launches, by which point substantial real-world data has accumulated. The government considers therapeutic advantage over alternatives, comparative effectiveness across clinical and patient-reported outcomes, impact on specific populations, and ability to address unmet medical needs. Real-world evidence plays a growing role in each of these assessments.
A review of reassessments published between 2018 and 2023 found that when real-world evidence was included, it most often addressed uncertainties about primary and secondary treatment outcomes (33% and 31% of cases, respectively). Registry data was the most common source, used in 57% of cases, with electronic health records and insurance claims playing smaller roles.
Medical Devices Follow Similar Principles
Post-launch research isn’t limited to pharmaceuticals. Medical device manufacturers are required to maintain post-market surveillance systems that actively and systematically collect data on device quality, performance, and safety throughout the product’s entire lifetime. Under European regulations, manufacturers must conduct post-market clinical follow-up to confirm safety and performance, identify previously unknown side effects and emerging risks, ensure the benefit-risk balance remains acceptable, and flag systematic misuse.
Device manufacturers most commonly use clinical registries (68% of manufacturers surveyed) and single-arm studies (68%) for this work. The most frequently tracked safety outcomes are complications like infections (79% of studies) and device performance metrics such as failure rates (68%). On the effectiveness side, researchers focus on functional status and surrogate endpoints like biomarkers or diagnostic test results.
For both drugs and devices, the underlying principle is the same: approval marks the beginning of a product’s evaluation, not the end. The real test comes when millions of people with varying health conditions, ages, and circumstances start using it in their daily lives, and post-launch research is the system built to learn from that experience.